McAllister, Sean D.
California Pacific Medical Center Research Institute, San Francisco, CA, United States
Abstract
![NIH thumb site](https://freedomwares.ca/wp-content/uploads/2016/06/NIH-thumb-site.jpg)
The first aim of this application is to determine if selective CB2 receptor agonists can inhibit metastatic breast cancer cell proliferation and invasiveness as effectively as mixed CB1/CB2 receptor agonists. CB2 agonists do not produce psychotropic side effects, as compared to agonists with CB1 receptor activity, and would potentially be more useful clinically. Next, signal transduction pathways potentially involved in control of breast cancer cell proliferation and invasion by cannabinoids will be evaluated. The next aim will be to evaluate the magnitude of selective efficacy that cannabinoids have for inhibiting breast cancer cell proliferation, migration, and inducing cell death. We will also define the relationship of these effects to alterations in downstream targets. The cannabinoid, cannabidiol, does not interact with CB1 and CB2 receptors, but can inhibit breast cancer cell proliferation and invasiveness.
The third aim will be to determine if activation of a cannabinoid receptor subtype and specific signaling pathways are responsible for the effects of cannabidiol. The final aim will be to determine if cannabinoids can inhibit breast cancer metastasis in vivo. Testing the hypotheses outlined in the application may lead to the development of effective inhibitors of breast, and perhaps other, cancers. This research may also elucidate novel mechanisms related to the anticancer activity of cannabinoids, and will serve to develop the career of the candidate in the field of cancer
biology. ? ? ? ?
The third aim will be to determine if activation of a cannabinoid receptor subtype and specific signaling pathways are responsible for the effects of cannabidiol. The final aim will be to determine if cannabinoids can inhibit breast cancer metastasis in vivo. Testing the hypotheses outlined in the application may lead to the development of effective inhibitors of breast, and perhaps other, cancers. This research may also elucidate novel mechanisms related to the anticancer activity of cannabinoids, and will serve to develop the career of the candidate in the field of cancer
biology. ? ? ? ?
- Agency
- National Institute of Health (NIH)
- Institute
- National Cancer Institute (NCI)
- Type
- Research Scientist Development Award – Research & Training (K01)
- Project #
- 1K01CA111723-01A2
- Application #
- 7147321
- Study Section
- Special Emphasis Panel (ZCA1-RTRB-A (M1))
- Program Officer
- Eckstein, David J
- Project Start
- 2006-09-01
- Project End
- 2010-08-31
- Budget Start
- 2006-09-01
- Budget End
- 2007-08-31
- Support Year
- 1
- Fiscal Year
- 2006
- Total Cost
- $143,532
- Indirect Cost
- Name
- California Pacific Medical Center Research Institute
- Department
- Type
- DUNS #
- 071882724
- City
- San Francisco
- State
- CA
- Country
- United States
- Zip Code
- 94107
McAllister, Sean D; Murase, Ryuichi; Christian, Rigel T et al. (2011) Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat 129:37-47 |
Marcu, Jahan P; Christian, Rigel T; Lau, Darryl et al. (2010) Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol Cancer Ther 9:180-9 |
McAllister, Sean D; Christian, Rigel T; Horowitz, Maxx P et al. (2007) Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther 6:2921-7 |